Welcome to our dedicated page for West Pharm Svcs SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The West Pharmaceutical Services, Inc. (NYSE: WST) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. West is a Pennsylvania corporation in the surgical and medical instrument manufacturing industry, focused on injectable drug administration for pharmaceutical, biotechnology and generic drug customers.
West’s SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Recent 8-K filings have covered topics such as second- and third-quarter 2025 financial results, updated revenue and adjusted-diluted EPS guidance, and changes in senior leadership, including the appointment of a new Senior Vice President & Chief Financial Officer and the planned departure of a senior legal executive. Other 8-Ks reference the furnishing of earnings press releases and investor presentation materials.
For investors analyzing WST, the 10-K and 10-Q filings contain detailed information on the Proprietary Products and Contract-Manufactured Products segments, High-Value Product Components and Delivery Devices, capital spending, cash flow, and risk factors. Form 8-K filings provide timely updates on material events, including financial results, dividends, guidance changes and executive compensation arrangements.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify segment performance, guidance revisions and notable risk disclosures. Real-time updates from the SEC’s EDGAR system ensure that new West filings appear promptly. Users can also review filings that relate to executive appointments, compensation terms and other governance matters, which are often detailed in exhibits to Form 8-K. This page serves as a focused resource for reviewing West Pharmaceutical Services’ regulatory history and ongoing reporting.
West Pharmaceutical Services SVP & CFO Robert W. McMahon reported equity award activity on February 11, 2026. He converted 4,230.525 restricted stock units into the same number of common shares at an exercise price of $0.
To cover tax obligations, 1,250.034 common shares were withheld at $246.16 per share, leaving 2,980.491 common shares held directly after the transaction. He also reported 8,462.052 restricted stock units remaining outstanding following these events.
West Pharmaceutical Services, Inc. reported steady growth for the fourth quarter and full year 2025 and issued 2026 guidance. Fourth-quarter net sales were $805.0 million, up 7.5% with 3.3% organic growth, and adjusted diluted EPS rose 12.1% to $2.04.
For 2025, net sales reached $3.074 billion, increasing 6.3% with 4.3% organic growth, while adjusted diluted EPS grew 8.0% to $7.29. Operating cash flow was $754.8 million and free cash flow rose 69.6% to $468.9 million, reflecting lower capital spending.
Management expects 2026 net sales between $3.215 billion and $3.275 billion, implying 5% to 7% organic growth, and adjusted diluted EPS between $7.85 and $8.20, or 7.7% to 12.5% growth. Guidance assumes a mid-2026 close for the SmartDose 3.5mL sale to AbbVie.
West Pharmaceutical Services director reports equity awards and holdings. Director Janet Haugen reported beneficial ownership of 1,320.262 shares of West Pharmaceutical common stock, which includes 1,071 restricted stock units and related dividend equivalents that will vest in full on the date of the next annual shareholder meeting under the Deferred Compensation Plan for Outside Directors.
She also acquired 46 phantom stock units on 12/31/2025, each linked to one share of common stock at a reference price of $275.14, increasing her total phantom stock units to 208.3. These phantom units are to be settled in shares of stock when she terminates service as a director.
West Pharmaceutical Services executive Norman D. Finch, Jr., who serves as SVP, General Counsel & Corporate Secretary, reported equity awards in the company’s stock. On December 8, 2025, he received 192 restricted stock units, each representing a right to receive one share of common stock. This award is scheduled to vest in four equal installments beginning December 8, 2026, providing a staggered long-term incentive.
On the same date, Finch also received a stock option covering 459 shares of West Pharmaceutical common stock at an exercise price of $269.08 per share, with an expiration date of December 8, 2035. Both the RSUs and the option are reported as directly owned and reflect standard equity-based compensation for a senior officer.
West Pharmaceutical Services reported insider equity holdings for a senior executive. The reporting person is an officer of the company, serving as SVP, General Counsel and Corporate Secretary. The filing shows derivative holdings including 192 restricted stock units tied to West Pharmaceutical common stock, which vest in four equal installments beginning on December 8, 2026. It also discloses a stock option covering 459 shares of common stock with an exercise price of $269.08 per share and an expiration date of December 8, 2035. These details outline part of the executive’s long-term, equity-based compensation linked to the company’s share performance.
West Pharmaceutical Services (WST): Schedule 13G/A filed by The Vanguard Group
The Vanguard Group reported beneficial ownership of 9,704,948 shares of WST common stock, representing 13.49% of the class as of 09/30/2025. Vanguard reported 0 shares with sole voting power and 422,261 with shared voting power. It reported 9,018,715 shares with sole dispositive power and 686,233 with shared dispositive power.
Vanguard states the securities are held in the ordinary course and not to influence control. Its clients have the right to receive dividends or sale proceeds, and no single client’s interest exceeds 5%.
West Pharmaceutical Services (WST) reported higher Q3 results. Net sales rose to $804.6 million from $746.9 million, driven primarily by the Proprietary Products segment ($647.5 million vs. $601.4 million). Gross profit increased to $294.3 million, and operating profit was $167.6 million. Net income was $140.0 million, with diluted EPS of $1.92, up from $1.85.
For the first nine months, net sales reached $2,269.1 million versus $2,144.4 million. Operating cash flow was strong at $503.7 million, while capital expenditures were $209.8 million. Cash and cash equivalents were $628.5 million at September 30, 2025, and long-term debt stood at $202.7 million, with $497.7 million available under the $500 million revolver. The company spent $134.0 million on share repurchases year‑to‑date and paid dividends of $45.4 million.
Product mix remained favorable: High‑Value Product components represented 48% of Q3 sales. The company recorded $21.9 million of restructuring and related charges year‑to‑date under a 2025 plan that targets approximately $30–$32 million of total charges and annualized savings of $35–$40 million. The effective tax rate was 19.8% in Q3 and 20.1% year‑to‑date.
West Pharmaceutical Services, Inc. furnished an 8-K announcing its third-quarter 2025 financial results. The company provided a press release and an investor presentation as exhibits.
The materials were furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD). The company noted these items are furnished, not filed, and therefore are not subject to Section 18 liabilities. The press release (Exhibit 99.1) and presentation (Exhibit 99.2) are dated October 23, 2025.
Janet Brutschea Haugen, a director of West Pharmaceutical Services, Inc. (WST), reported transactions dated 09/30/2025. The Form 4 discloses a disposition of 1,319.348 shares of Common Stock and the acquisition of 48 Phantom Stock Units on the same date. The filing shows 162.161 shares reported as beneficially owned following the reported derivative transaction. Footnotes state the 1,071 restricted stock units and dividend equivalents underlying part of the position will vest in full at the next annual shareholder meeting and be distributable under the Deferred Compensation Plan for Outside Directors, and that phantom stock units are settled by delivery of shares upon the reporting person’s termination as a director. The form is signed by an agent on behalf of Ms. Haugen on 10/02/2025.
West Pharmaceutical Services reported a leadership change in its legal organization. Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the company following a transition period. The company and Ms. MacKay plan to determine an appropriate transition that will end no later than December 31, 2025, to support a smooth handover of responsibilities. Until her departure, she will continue in her current role overseeing legal and corporate secretary duties. The company publicly thanked her for her service and contributions and expressed well wishes for her future endeavors.